Earnings Ahead

NRIX - Nurix Therapeutics

9.74 0.12 1.25

Nurix Therapeutics

Nurix Therapeutics

About

Profile


Headquarters

San Francisco, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

NRIX



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Nurix Therapeutics GAAP EPS of -$0.68 beats by $0.06, revenue of $18.47M beats by $0.52M
  • Nurix announces collaboration with Seagen to advance a new class of cancer therapeutics
  • Nurix Therapeutics GAAP EPS of -$0.75 beats by $0.13, revenue of $12.69M beats by $1.73M
  • Gilead licenses protein degrader from Nurix Therapeutics
  • Nurix Therapeutics GAAP EPS of -$0.87 misses by $0.10, revenue of $6.78M misses by $10.39M
  • Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
  • Nurix Therapeutics to raise $40M via registered direct offering
  • Nurix Therapeutics announces $55M registered direct offering
  • Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M
  • FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.
  • Nurix upgraded to overweight at Wells Fargo on promise of lymphoma candidate
  • Nurix Therapeutics plunges on R&D Day
  • Catalyst Watch: JPMorgan event, Best Buy earnings and McDonald's drama
  • Nurix higher after announcing pre-clinical data for cancer candidates
  • Nurix Therapeutics Q1 GAAP EPS of -$0.95 misses by $0.09, revenue of $9.6M beats by $0.33M
  • Nurix begins dosing in phase 1 trial of DeTIL-0255 for gynecological cancers
  • Nurix Therapeutics awarded innovation medicine tag for solid tumors therapy in UK
  • Nurix Therapeutics GAAP EPS of -$0.85 misses by $0.16, revenue of $7.4M misses by $5.79M
  • Nurix Therapeutics gets FDA greenlight for DeTIL-0255 Phase 1 trial
  • Nurix shows partial response in early-stage trial for NX-2127 in blood cancer

Earnings History

Date EPS / Forecast Revenue / Forecast
February 15, 2022 - / -0.6114 - / 13.02M
January 27, 2022 -0.85 / -0.6825 7.4M / 13.19M
October 14, 2021 -0.65 / -0.6214 10.25M / 8.54M Beat!
July 13, 2021 -0.6 / -0.535 7.09M / 8.23M
April 13, 2021 -0.63 / -0.4525 5.01M / 5.01M
February 16, 2021 -0.51 / -0.534 6.69M / 3.95M Beat!
October 14, 2020 -0.21 / - 10.58M / - Beat!
July 2, 2020 0.67 / - 4.18M / - Beat!
June 10, 2020 -1.09 / - 2.86M / - Beat!
May 5, 2020 -1.91 / - 31.12M / - Beat!
Date Price Open High Low Vol Change ER
After hrs 17.58 0%
Feb 15, 2022 17.58 16.82
17.81
16.82
272.12K 7.59%
Feb 14, 2022 16.34 17.47
17.79
16.09
431.03K -7.05%
Feb 11, 2022 17.58 18.59
18.81
17.16
221.51K -4.97%
Feb 10, 2022 18.50 19.17
20.20
18.29
314.97K -6.04%
Feb 9, 2022 19.69 19.02
20.00
19.02
322.09K 2.55%
 
Feb 8, 2022 19.20 18.76
19.33
18.44
544.24K 1.27%
Feb 7, 2022 18.96 18.24
19.18
18.12
347.84K 4.18%
Feb 4, 2022 18.20 17.51
18.27
17.39
372.95K 3.17%
Feb 3, 2022 17.64 18.06
18.94
17.40
304.66K -5.52%
Feb 2, 2022 18.67 18.92
19.25
18.52
377.43K -1.48%
Feb 1, 2022 18.95 18.64
19.10
18.18
348.74K 1.77%
Jan 31, 2022 18.62 17.89
18.77
17.42
477.44K 5.44%
Jan 28, 2022 17.66 16.81
18.16
16.67
504.79K 2.14%
Jan 27, 2022 17.29 18.56
18.77
17.10
316.97K -6.64%
Jan 26, 2022 18.52 19.61
20.30
18.38
304.28K -5.03%
Jan 25, 2022 19.50 19.36
19.90
18.76
271.74K -0.61%
Jan 24, 2022 19.62 18.93
19.64
18.50
683.88K 2.67%
Jan 21, 2022 19.11 18.66
19.81
18.50
446.77K 1.16%
Jan 20, 2022 18.89 19.50
20.50
18.70
319.99K -3.08%
Jan 19, 2022 19.49 19.85
20.33
19.14
523.46K -2.01%
Jan 18, 2022 19.89 22.70
22.70
19.77
459.99K -14.41%